Kanaly Robert A, Matsui Saburo, Hanaoka Tomoyuki, Matsuda Tomonari
Department of Technology and Ecology, Graduate School of Global Environmental Studies, Kyoto University, Kyoto 606-8501, Japan.
Mutat Res. 2007 Dec 1;625(1-2):83-93. doi: 10.1016/j.mrfmmm.2007.05.006. Epub 2007 May 21.
Methods for determining the differential susceptibility of human organs to DNA damage have not yet been explored to any large extent due to technical constraints. The development of comprehensive analytical approaches by which to detect intertissue variations in DNA damage susceptibility may advance our understanding of the roles of DNA adducts in cancer etiology and as exposure biomarkers at least. A strategy designed for the detection and comparison of multiple DNA adducts from different tissue samples was applied to assess esophageal and peripherally- and centrally-located lung tissue DNA obtained from the same person. This adductome approach utilized LC/ESI-MS/MS analysis methods designed to detect the neutral loss of 2'-deoxyribose from positively ionized 2'-deoxynucleoside adducts transmitting the M+H>M+H-116 transition over 374 transitions. In the final analyses, adductome maps were produced which facilitated the visualization of putative DNA adducts and their relative levels of occurrence and allowed for comprehensive comparisons between samples, including a calf thymus DNA negative control. The largest putative adducts were distributed similarly across the samples, however, differences in the relative amounts of putative adducts in lung and esophagus tissue were also revealed. The largest-occurring lung tissue DNA putative adducts were 90% similar (n=50), while putative adducts in esophagus tissue DNA were shown to be 80 and 84% similar to central and peripheral lung tissue DNA respectively. Seven DNA adducts, N(2)-ethyl-2'-deoxyguanosine (N(2)-ethyl-dG), 1,N(6)-etheno-2'-deoxyadenosine (varepsilondA), alpha-S- and alpha-R-methyl-gamma-hydroxy-1,N(2)-propano-2'-deoxyguanosine (1,N(2)-PdG(1), 1,N(2)-PdG(2)), 3-(2'-deoxyribosyl)-5,6,7,8-tetrahydro-8-hydroxy-pyrimido[1,2-a]purine-(3H)-one (8-OH-PdG) and the two stereoisomers of 3-(2'-deoxyribosyl)-5,6,7,8-tetrahydro-6-hydroxypyrimido[1,2-a]purine-(3H)-one (6-OH-PdG) were unambiguously detected in all tissue DNA samples by comparison to authentic adduct standards and stable isotope dilution and their identities were matched to putative adducts detected in the adductome maps.
由于技术限制,尚未对确定人体器官对DNA损伤的差异敏感性的方法进行大规模探索。开发全面的分析方法以检测DNA损伤敏感性的组织间差异,至少可能会增进我们对DNA加合物在癌症病因学中的作用以及作为暴露生物标志物的理解。一种设计用于检测和比较来自不同组织样本的多种DNA加合物的策略,被应用于评估从同一人身上获取的食管以及肺外周和肺中央组织的DNA。这种加合物组学方法利用了液相色谱/电喷雾串联质谱分析方法,该方法旨在检测在374个跃迁上传递[M+H]>[M+H - 116]跃迁的正离子化2'-脱氧核苷加合物中2'-脱氧核糖的中性丢失。在最终分析中,生成了加合物组图谱,这有助于可视化假定的DNA加合物及其相对出现水平,并允许对包括小牛胸腺DNA阴性对照在内的样本进行全面比较。最大的假定加合物在各样本中的分布相似,然而,也揭示了肺和食管组织中假定加合物相对含量的差异。在肺组织DNA中出现最多的假定加合物有90%相似(n = 50),而食管组织DNA中的假定加合物与肺中央和肺外周组织DNA分别有80%和84%相似。通过与真实加合物标准品比较和稳定同位素稀释,在所有组织DNA样本中明确检测到了七种DNA加合物,即N(2)-乙基-2'-脱氧鸟苷(N(2)-乙基-dG)、1,N(6)-乙烯基-2'-脱氧腺苷(εdA)、α-S-和α-R-甲基-γ-羟基-1,N(2)-丙烷-2'-脱氧鸟苷(1,N(2)-PdG(1)、1,N(2)-PdG(2))、3-(2'-脱氧核糖基)-5,6,7,8-四氢-8-羟基嘧啶并[1,2-a]嘌呤-(3H)-酮(8-OH-PdG)以及3-(2'-脱氧核糖基)-5,6,7,8-四氢-6-羟基嘧啶并[1,2-a]嘌呤-(3H)-酮(6-OH-PdG)的两种立体异构体,并且它们的身份与加合物组图谱中检测到的假定加合物相匹配。